"Designing Growth Strategies is in our DNA"
Bovine Respiratory Disease (BRD) refers to one of the most common and expensive diseases to occur to the cattle worldwide. Bovine respiratory disease occurs due to various infections including viruses, bacteria and parasites viruses, includes bovine herpes virus (IBR); bovine parainfluenza virus (PI-3); bovine respiratory syncytial virus (BRSV); bovine viral diarrhea virus (BVD), and bovine coronavirus (BCV). These factors affect the immune system of the calf, leading to its weakening to cause diseases such as pneumonia. The bovine respiratory disease is also called a disease complex, due to the variety of causes such as various pathogens leading to its occurrence in bovines. According to the estimates of the Beef Cattle Research Council, Bovine respiratory disease accounts for 65-80% of the morbidity and 45-75% of the mortality in the feed yards.
Growing prevalence of several causative agents for respiratory diseases among bovines, rapidly changing environmental factors, and expanding cattle population, which is driven by the rising demand for better quality bovine meat and products. These factors are anticipated to drive the growth of the global respiratory disease treatment market. Growing awareness among consumers regarding healthy meat and animal health management practices and environment protection guidelines additionally are some of the factors driving the growth of the global respiratory disease treatment market.
To get information on various segments, share your queries with us
The factors limiting the growth of global bovine respiratory disease treatment market includes the complexities related in the diagnosis of bovine respiratory disease, increasing cost of animal healthcare, lack of animal healthcare awareness in developing markets and shortage of skilled veterinary professionals in the emerging markets.
Some of the major companies that are present in the global bovine respiratory disease treatment market are Zoetis, Intervet Inc., Virbac, Boehringer Ingelheim International GmbH, Ceva, Elanco, Vetoquinol S.A., Bimeda, Inc., Bayer AG, and others.
· Lower Respiratory Tract Infection
· Upper Respiratory Tract Infection
· Nonsteroidal Anti-Inflammatory Drugs (Nsaids)
By End User
· Veterinary Hospitals
· Veterinary Clinics
· North America (USA and Canada)
· Europe (UK, Germany, France, Italy, Spain, Scandinavia and Rest of Europe)
· Asia Pacific (Japan, China, India, Australia, Southeast Asia and Rest of Asia Pacific)
· Latin America (Brazil, Mexico and Rest of Latin America)
· Middle East & Africa (South Africa, GCC and Rest of Middle East & Africa)
In 2018, among end user, veterinary hopsitals dominated the global bovine respiratory disease treatment market due to the rising prevalence of respiratory diseases among cattle and more number of procedures are carried out in veterinary hospital . The veterinary hospitals segment is projected to growt at compartively higher CAGR during the forecast period.
North America dominated the global bovine respiratory disease treatment market in 2018, due to a number of factors such as the large bovine animal pool, increasing prevalence of bovine respiratory disease, and increasing expenditure on bovine health. Asia Pacific is anticipated to grow at significant CAGR due to large livestock animal pool, increasing incidences of bovine disorders such as bovine respiratory disease, increasing awareness of animal welfare and introduction of government initiatives towards the treatment of bovine respiratory diseases.